P3 Health Partners (PIII) Q2 2026 earnings review
A $54M EBITDA 'Beat' Built on Accounting and Expensive Capital
On the surface, P3 Health Partners delivered a stunning Q2 turnaround, posting $54.4M in Adjusted EBITDA and raising full-year guidance. However, a deeper dive reveals severe earnings quality issues. First, $44.9M of the $97.8M medical margin came from favorable prior-year development (PYD) and settlements—meaning core operations generated just a fraction of the reported profits. Second, while Net Income swung to a positive $15.7M, operating cash flow for the first half was profoundly negative (-$89.4M). Finally, the company's balance sheet 'fix' involved issuing Series A-D preferred stock carrying staggering 13.5% to 19.5% cumulative dividends, which siphoned off $9.6M this quarter and drove Class A Common EPS to a loss of $0.63. The core business is improving, but common shareholders are footing a massive bill.
🐂 Bull Case
Even excluding the massive one-time PYD benefit, Q2 core medical margin was $168 PMPM, a Reversing trend from negative core margins a year ago. Per-member capitated revenue increased 15% YoY, proving contract renegotiations are bearing fruit.
While the broader Medicare Advantage industry faces 6-7% cost inflation, P3 continues to report flat medical cost trends, validating their Care Enablement Model and tight utilization management.
🐻 Bear Case
Despite reporting $18.7M in H1 Net Income, operating cash flow was -$89.4M. The company burned cash paying down $44M in health plan settlements and $32M in claims payables, proving the 'profits' are largely non-cash accounting adjustments.
The $250M debt-to-preferred equity conversion saved the company from default but introduced cumulative dividend rates of up to 19.5%. This effectively eliminates any near-term earnings potential for Class A common stock.
⚖️ Verdict: 🔴
Bearish. While management's operational turnaround is yielding real PMPM improvements, the financial engineering required to keep the company afloat has destroyed common shareholder value. The implied H2 guidance shows management knows the Q2 windfall will not repeat.
Key Themes
The PYD Illusion and Implied H2 Deceleration
A crucial data point contradicts the positive 'structural turnaround' narrative: H2 implied guidance. Management raised FY26 Adjusted EBITDA guidance to $80-$110M. However, H1 already generated $80.2M in Adjusted EBITDA (buoyed by $61.9M in total H1 PYD and settlements). This implies H2 Adjusted EBITDA will Decelerate violently to just $14.8M at the midpoint. This confirms that Q2's massive profitability was an accounting pull-forward, not a permanent new baseline.
Toxic Preferred Equity Wipes Out Common Shareholders
To solve its balance sheet crisis and meet NASDAQ requirements, P3 issued four tranches of Preferred Stock (Series A through D). A review of the balance sheet reveals catastrophic terms for common shareholders: $81.3M of Series C and $43.2M of Series D carry a 19.5% cumulative dividend rate. In Q2 alone, these instruments accrued $9.57M in dividends. Consequently, while consolidated Net Income was $15.7M, Net Loss Attributable to Class A Common Stockholders was -$2.1M. This structure is highly dilutive and Reversing value away from equity holders.
Shrinking to Grow: Network Rationalization
At-risk membership Decelerated by 10% YoY to 105,000 members. However, this is an intentional, strategic Driver. By exiting unprofitable payer contracts and pruning underperforming network affiliates, P3 has dramatically improved the quality of its remaining risk pools, directly contributing to the 15% YoY growth in capitated revenue PMPM.
Technology & Workflow: 'P3 is-door' and 24/7 Triage
A key Driver of the flat medical cost trend is the integration of new operational technology and workflows. Management previously highlighted the rollout of the 'P3 is-door' provider engagement program and a new 24/7 clinical call center targeted at high-risk members. These initiatives successfully diverted avoidable emergency department visits, helping push medical claims expense down by 15% YoY ($268.5M vs $321.1M in 25Q2).
Macro: Defying Industry Cost Inflation
While large managed care organizations and MA peers are reporting mid-to-high single-digit medical cost inflation due to elevated utilization, P3 has maintained a Stable, flat medical cost trend. By concentrating 62% of their membership with highly delegated 'Tier 1' providers, they have insulated themselves from the worst of the macro utilization headwinds.
Other KPIs
Accelerating dramatically by 391% YoY from $4.1M in 25Q2. This massive jump points to increased fee-for-service, care management fees, or potentially shared savings bonuses tied to the settlement true-ups that buoyed the quarter.
Decelerating severely compared to -$50.1M in H1 2025. The company recognized phantom accounting profits via PYD while simultaneously burning cash to settle $44.2M in health plan payables and $32.7M in historical claims.
Guidance
Accelerating significantly from the previous midpoint of $40M, and a massive reversal from the FY25 loss of $161.3M. However, as noted in the themes, with $80.2M already banked in H1 due to PYD, this implies a severe sequential Deceleration in H2 to just ~$14.8M at the midpoint.
Stable. The midpoint of $1.55B is roughly flat year-over-year compared to FY25's $1.46B, perfectly reflecting the dynamic of a 10% shrinking membership base offset by 15% higher per-member funding rates.
Accelerating sharply from FY25's $17 PMPM and the prior guidance range of $149 - $180. Like the EBITDA metric, this is heavily skewed by H1's prior-year development adjustments.
Key Questions
H2 Implied Deceleration
You generated $80.2M in Adjusted EBITDA in the first half, heavily aided by PYD and settlements. Your full-year guidance midpoint of $95M implies just $15M of EBITDA in the second half. Is this H2 run-rate the true baseline earnings power of the business going forward?
Cash Flow vs Net Income Divergence
You reported $18.7M in H1 Net Income, yet burned $89.4M in operating cash flow due to massive pay-downs of claims and health plan settlements. When do you expect operating cash flow to turn positive and align with your Adjusted EBITDA?
Path to Retiring 19.5% Preferred Equity
With Series C and D Preferred Stock carrying 19.5% cumulative dividends, the dividend burden is stripping all value from common shareholders. What is the explicit strategic timeline and mechanism for refinancing or retiring this highly dilutive capital?
Visibility into Future PYD
Given that nearly half of this quarter's medical margin came from prior year development, what changes have you made to your reserving methodology, and should we expect negative true-ups down the line if utilization unexpectedly spikes?